The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan

Journal of Urology

Volumn 170, Issue 1, 2003, Pages 78-81

  Wu, Tony T ^a   Hsu, Yen Shen ^b   Wang, Jyh Seng ^b   Lee, Ying Huei ^b   Huang, Jong Khing ^b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Cadherins; Gene expression; Prostate; Prostatic neoplasms; Taiwan

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; FOLLOW UP; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM; TAIWAN;

EID: 0038679417     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000065802.92406.a6     Document Type: Article

References (20)

1. Cancer Registration System, Department of Health, Taiwan, Republic of China. Available at http://crs.cph.ntu.edu.tw. Accessed December 16, 2002
2. Quinn, M. and Babb, P.: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int, 90: 162, 2002
3. Zhau, H. E., Zhao, L.-S., Chung, L. W. K., Chen, B.-Q., Troncoso, P., Kao, C. et al: Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol, 1: 51, 1995
4. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol, 152: 1831, 1994
5. Dillioglugil, O., Leibman, B. D., Kattan, M. W., Seale-Hawkins, C., Wheeler, T. M. and Scardino, P. T.: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93 1997
6. Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C.: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol, 20: 286, 1996
7. Oxley, J. D., Winkler, M. H., Parry, K., Brewster, S., Abbott, C. and Gillatt, D. A.: p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int, 89: 27, 2002
8. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol, 156: 1511, 1996
9. Stackhouse, G. B., Sesterhenn, I. A., Bauer, J. J., Mostofi, F. K., Connelly, R. R., Srivastava, S. K. et al: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol, 162: 2040, 1999
10. Schipper, J. H., Frixen, U. H., Behrens, J., Unger, A., Jahnke, K. and Birchmeier, W.: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res, 51: 6328, 1991
11. Quinn, D. I., Henshall, S. M., Head, D. R. Golovsky, D., Wilson, J. D., Brenner, P. C. et al: Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated by radical prostatectomy. Cancer Res, 60: 1585, 2000
12. Yang, G., Stapleton, A. M., Wheeler, T. M., Truong, L. D., Timme, T. L., Scardino, P. T. et al: Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res, 2: 399, 1996
13. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. et al: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996
14. Matsushima, H., Kitamura, T., Goto, T., Hosaka, Y., Homma, Y. and Kawabe, K.: Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol, 158: 2278, 1997
15. Mareel, M., Boterberg, T., Noe, V., Bruyneel, E. and Bracke, M.: Molecular aspects of cancer metastasis: extracellular regulation of the E-cadherin/catenin complex. Int J Dev Biol, suppl., 1: 65S, 1996
16. Loric, S., Paradis, V., Gala, J. L., Berteau, P., Bedossa, P., Benoit, G. et al: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer, 37: 1475, 2001
17. De Marzo, A. M., Knudsen, B., Chan-Tack, K. and Epstein, J. I.: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology, 53: 707, 1999
18. Ruijter, E., van de Kaa, C., Aalders, T., Ruiter, D., Miller, G., Debruyne, F. et al: Heterogenous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol, 11: 276, 1998
19. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F., Oosterhof, G. O. et al: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res, 54: 3929, 1994
20. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. A. et al: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA, 87: 8751, 1990